gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AVTXHealthcarePharmaceuticals

Avalo Therapeutics, Inc. Common Stock (AVTX)

$7.07−2.48%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$7.07▼ 56.06% in range
Nov 4, 2025Low $6.75 · High $22.87Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Avalo Therapeutics closed at $7.07 on Nov 4, down 2.48%, 69.1% below its 52-week closing high. Volume of 1.4M shares was 0.48× its 20-day average (below normal).

Split-adjusted performance: -48.0% over one month, -67.6% over six months, -57.6% over one year.

Short interest was 12.0M shares at the Oct 15 settlement, up 4.9% from the prior report (24.6% of float, 13.0 days to cover).

Market cap$379.2M53.6M shares
Revenue · quarter$0.00—
Diluted EPS$-0.83—
P/E · TTM—P/S 6,426.5×
Net margin—
Dividend yieldNone
52-week range6.75 – 22.87−69.1% from high
Volume1.4M0.48× 20-day avg
Volatility · 60d113.6%Annualised
Short % of float24.6%13.0 days to cover
Net cash$400.3MCash $400.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.7%1M −48.0%3M −62.2%6M −67.6%YTD −61.1%1Y −57.6%3Y −68.3%5Y −99.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum13
Revenue growth—
Net margin—
Value (low P/E)—
Size57

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short12.0M+4.9% vs prior
Days to cover13.0Settled Oct 15
% of float24.6%
Short vol. 10d38.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AVTXAvalo Therapeutics$7.07−2.48%−67.6%———$379.2M
LYELLyell Immunopharma$15.43+43.27%−26.0%−50.0%−1118875.0%—$378.1MCompare
RZLTRezolute, Inc. Common Stock (NV)$3.96−1.25%+26.1%———$383.0MCompare
MPLTMapLight Therapeutics$6.71−1.47%−76.9%———$372.9MCompare
CTNMContineum Therapeutics$9.79+1.03%−34.5%———$368.3MCompare
BLSMBlossomHill Therapeutics$12.38−0.24%————$393.5MCompare
AVIRAtea Pharmaceuticals$4.46+6.95%−21.1%———$357.7MCompare
ASMBAssembly Biosciences$19.87−0.25%−36.6%+38.9%−28.8%—$404.6MCompare
IRDOpus Genetics$4.27+8.65%−18.8%−73.8%−1072.6%—$355.2MCompare

News about Avalo Therapeutics

All news →
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® IndexesGlobeNewswire Inc. · Jun 26, 2026▲ PositiveAvalo Therapeutics Announces Pricing of $375 Million Public OfferingGlobeNewswire Inc. · May 6, 2026▲ Positive

Quick answers

What does Avalo Therapeutics do?
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases.
What is AVTX's market cap?
$379.16M, based on the Nov 4 close of $7.07.
Does Avalo Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AVTX is sold short?
12.0M shares, 24.6% of float, as of Oct 15, 2026.
What sector is AVTX in?
Healthcare, in the Pharmaceuticals industry.

About Avalo Therapeutics

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

HQ: Wayne, PA33 employeesListed Nov 13, 2015avalotx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology